Acquisition

UDG Healthcare acquires MicroMass, for up to $75.8 million

UDG Healthcare acquires MicroMass, for up to $75.8 million

By

The company also this year has purchased Vynamic and Cambridge BioMarketing.

Digital Healthcare: Is It For Real?

Digital Healthcare: Is It For Real?

The coming digital revolution will change a lot of things, but I guarantee this: It won't replace the importance of the patient-physician relationship.

Five things for pharma marketers to know: Monday, July 31, 2017

Five things for pharma marketers to know: Monday, July 31, 2017

By

FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi

Five things for pharma marketers to know: Tuesday, July 18, 2017

Five things for pharma marketers to know: Tuesday, July 18, 2017

By

Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy

Five things for pharma marketers to know: Tuesday, July 11, 2017

Five things for pharma marketers to know: Tuesday, July 11, 2017

By

Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics

Five things for pharma marketers to know: Friday, June 2, 2017

Five things for pharma marketers to know: Friday, June 2, 2017

By

Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation

Five things for pharma marketers to know: Tuesday, May 16, 2017

Five things for pharma marketers to know: Tuesday, May 16, 2017

By

A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms

MM&M's top 5 stories in February 2017

MM&M's top 5 stories in February 2017

By

WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram

Five things for pharma marketers to know: Thursday, February 2, 2017

Five things for pharma marketers to know: Thursday, February 2, 2017

By

Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue

Five things for pharma marketers to know: Wednesday, January 4, 2017

Five things for pharma marketers to know: Wednesday, January 4, 2017

By

Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology

Five things for pharma marketers to know: Tuesday, December 20, 2016

Five things for pharma marketers to know: Tuesday, December 20, 2016

By

Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm

Five things for pharma marketers to know: Friday, December 9, 2016

Five things for pharma marketers to know: Friday, December 9, 2016

By

BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA

Five things for pharma marketers to know: Monday, November 28, 2016

Five things for pharma marketers to know: Monday, November 28, 2016

By

J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe

Five things for pharma marketers to know: Monday, November 14, 2016

Five things for pharma marketers to know: Monday, November 14, 2016

By

J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader

Five things for pharma marketers to know: Monday, October 24, 2016

Five things for pharma marketers to know: Monday, October 24, 2016

By

GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus

W2O acquires Pure Communications, plans to create new health and tech agency

W2O acquires Pure Communications, plans to create new health and tech agency

By

Pure Communications CEO Andrea Johnston will lead the combined agency.

Five things for pharma marketers to know: Monday, August 22, 2016

Five things for pharma marketers to know: Monday, August 22, 2016

By

Pfizer to acquire cancer drugmaker Medivation; Valeant names new CFO; Apple acquires health data startup

Five things for pharma marketers to know: Tuesday, August 2, 2016

Five things for pharma marketers to know: Tuesday, August 2, 2016

By

IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets

Omnicom to acquire BioPharm Communications

Omnicom to acquire BioPharm Communications

By

Omnicom recently reorganized its health agencies under the Omnicom Health Group umbrella.

Precision for Medicine acquires ACT Oncology

Precision for Medicine acquires ACT Oncology

By

The scientific services company expands its portfolio to include expertise in oncology clinical studies.

Five things for pharma marketers to know: Friday, September 25, 2015

Five things for pharma marketers to know: Friday, September 25, 2015

By

Teva acquires sensor-based inhaler; EU conditionally approves Amgen's cancer drug, Blincyto; Novartis CEO says targeted therapies may reduce unnecessary US healthcare spending

Savvy comms paves way for Walgreens Boots Alliance merger

Savvy comms paves way for Walgreens Boots Alliance merger

Walgreens Boots Alliance's global comms team works hand in hand to balance the complexities of a merger and create a unified strategy to inspire all stakeholders.

Five things for pharma marketers to know: Friday, August 7

Five things for pharma marketers to know: Friday, August 7

By

CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP

Five things for pharma marketers to know: Wednesday, August 5

Five things for pharma marketers to know: Wednesday, August 5

By

The FDA updates Gilenya's label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information

Five things for pharma marketers to know: Tuesday, August 4

Five things for pharma marketers to know: Tuesday, August 4

By

Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014

Five things for pharma marketers to know: Thursday, July 30

Five things for pharma marketers to know: Thursday, July 30

Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

By

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

Five things for pharma marketers to know: Monday, July 27

Five things for pharma marketers to know: Monday, July 27

By

Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend

Five things for pharma marketers to know: Wednesday, July 22

Five things for pharma marketers to know: Wednesday, July 22

By

Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed

Five things for pharma marketers to know: Friday, July 17

Five things for pharma marketers to know: Friday, July 17

By

Gilead will limit financial assistance to patients to pressure payers; Biogen reports another PML case related to Tecfidera; Valeant buys Egyptian drugmaker